ArticleDiabetology international2021

Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.

Fumio Sawano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.